Advertisement
Screener

AKEBIA THERAPEUTICS, INC. (AKBA) Increase (Decrease) in Inventories

2.8 / 5 stars · 68/120 Roast Me

AKEBIA THERAPEUTICS, INC. Increase (Decrease) in Inventories

AKEBIA THERAPEUTICS, INC. (AKBA) reported Increase (Decrease) in Inventories of $3.19 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInInventories · last filed 2026-08-05

  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-06-30 was $655.00K, a 91.44% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2026-03-31 was $2.54M, a 48.72% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-12-31 was $17.42M, a 105.01% increase year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for the quarter ending 2025-09-30 was -$6.90M, a 1365.87% decline year-over-year.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2025 was $23.13M, a 18.58% decline from fiscal 2024.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2024 was $28.40M, a 1017.27% increase from fiscal 2023.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2023 was $2.54M.
  • AKEBIA THERAPEUTICS, INC. increase (decrease) in inventories for fiscal 2022 was -$19.09M, a 176.51% decline from fiscal 2021.
Period endIncrease (Decrease) in Inventories 3 monthIncrease (Decrease) in Inventories 3 month as first filedIncrease (Decrease) in Inventories 6 monthIncrease (Decrease) in Inventories 6 month as first filedIncrease (Decrease) in Inventories 9 monthIncrease (Decrease) in Inventories 9 month as first filedIncrease (Decrease) in Inventories 12 monthIncrease (Decrease) in Inventories 12 month as first filed
2026-06-30$655.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$3.19M
10-Q · filed 2026-08-05
$20.61M
derived: sum of 3 quarters · filed 2026-08-05
$13.71M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$2.54M
10-Q · filed 2026-05-07
$19.96M
derived: sum of 2 quarters · filed 2026-05-07
$13.06M
derived: sum of 3 quarters · filed 2026-05-07
$20.71M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$17.42M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$10.52M
derived: sum of 2 quarters · filed 2026-02-26
$18.17M
derived: sum of 3 quarters · filed 2026-08-05
$23.13M
10-K · filed 2026-02-26
2025-09-30-$6.90M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$754.00K
derived: sum of 2 quarters · filed 2026-08-05
$5.71M
10-Q · filed 2025-11-10
$14.20M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$7.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$12.61M
10-Q · filed 2026-08-05
$21.10M
derived: sum of 3 quarters · filed 2026-08-05
$21.65M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$4.95M
10-Q · filed 2026-05-07
$13.45M
derived: sum of 2 quarters · filed 2026-05-07
$13.99M
derived: sum of 3 quarters · filed 2026-05-07
$28.92M
derived: sum of 4 quarters · filed 2026-05-07
2024-12-31$8.50M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$9.04M
derived: sum of 2 quarters · filed 2026-02-26
$23.97M
derived: sum of 3 quarters · filed 2026-02-26
$28.40M
10-K · filed 2026-02-26
2024-09-30$545.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10
$15.47M
derived: sum of 2 quarters · filed 2025-11-10
$19.91M
10-Q · filed 2025-11-10
$31.68M
derived: sum of 4 quarters · filed 2026-02-26
2024-06-30$14.93M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07
$19.36M
10-Q · filed 2025-08-07
$31.14M
derived: sum of 3 quarters · filed 2026-02-26
$32.73M
derived: sum of 4 quarters · filed 2026-02-26
2024-03-31$4.43M
10-Q · filed 2025-05-08
$16.21M
derived: sum of 2 quarters · filed 2026-02-26
$17.80M
derived: sum of 3 quarters · filed 2026-02-26
$14.32M
derived: sum of 4 quarters · filed 2026-02-26
2023-12-31$11.78M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$13.37M
derived: sum of 2 quarters · filed 2026-02-26
$9.89M
derived: sum of 3 quarters · filed 2026-02-26
$2.54M
10-K · filed 2026-02-26
2023-09-30$1.59M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
-$1.89M
derived: sum of 2 quarters · filed 2024-11-07
-$9.24M
10-Q · filed 2024-11-07
-$33.69M
derived: sum of 4 quarters · filed 2024-11-07
2023-06-30-$3.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
-$10.83M
10-Q · filed 2024-08-08
-$35.28M
derived: sum of 3 quarters · filed 2024-08-08
-$34.28M
derived: sum of 4 quarters · filed 2024-08-08
2023-03-31-$7.35M
10-Q · filed 2024-05-09
-$31.80M
derived: sum of 2 quarters · filed 2024-05-09
-$30.80M
derived: sum of 3 quarters · filed 2024-05-09
-$34.92M
derived: sum of 4 quarters · filed 2024-05-09
2022-12-31-$24.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14
-$23.45M
derived: sum of 2 quarters · filed 2024-03-14
-$27.58M
derived: sum of 3 quarters · filed 2024-03-14
-$19.09M
10-K · filed 2024-03-14
-$19.79M
10-K · filed 2023-03-10
2022-09-30$1.00M
derived: 10-Q 9 month − 10-K/A 6 month · filed 2023-11-08
-$3.13M
derived: sum of 2 quarters · filed 2023-11-08
$5.37M
10-Q · filed 2023-11-08
-$1.41M
10-Q · filed 2022-11-03
-$4.97M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30-$4.13M
derived: 10-K/A 6 month − 10-K/A 3 month · filed 2023-08-28
$4.36M
10-K/A · filed 2023-08-28
-$1.16M
10-Q · filed 2022-08-04
-$5.97M
derived: sum of 3 quarters · filed 2023-08-28
-$6.40M
derived: sum of 4 quarters · filed 2023-08-28
2022-03-31$8.49M
10-K/A · filed 2023-08-28
$5.25M
10-Q · filed 2022-05-09
-$1.84M
derived: sum of 2 quarters · filed 2023-08-28
-$2.27M
derived: sum of 3 quarters · filed 2023-08-28
$14.24M
derived: sum of 4 quarters · filed 2023-08-28
2021-12-31-$10.34M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
-$10.76M
derived: sum of 2 quarters · filed 2023-08-28
$5.75M
derived: sum of 3 quarters · filed 2023-08-28
$24.95M
10-K/A · filed 2023-08-28
$25.85M
10-K · filed 2022-03-01
2021-09-30-$428.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03
$16.09M
derived: sum of 2 quarters · filed 2022-11-03
$35.28M
10-Q · filed 2022-11-03
$35.53M
derived: sum of 4 quarters · filed 2023-08-28
2021-06-30$16.52M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04
$35.71M
10-Q · filed 2022-08-04
$35.96M
derived: sum of 3 quarters · filed 2023-08-28
$23.87M
derived: sum of 4 quarters · filed 2023-08-28
2021-03-31$19.19M
10-Q · filed 2022-05-09
$19.45M
derived: sum of 2 quarters · filed 2023-08-28
$7.35M
derived: sum of 3 quarters · filed 2023-08-28
$4.87M
derived: sum of 4 quarters · filed 2023-08-28
2020-12-31$252.00K
derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-08-28
-$11.84M
derived: sum of 2 quarters · filed 2023-08-28
-$14.33M
derived: sum of 3 quarters · filed 2023-08-28
-$6.16M
10-K/A · filed 2023-08-28
2020-09-30-$12.10M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04
-$14.58M
derived: sum of 2 quarters · filed 2021-11-04
-$6.42M
10-Q · filed 2021-11-04
-$5.84M
derived: sum of 4 quarters · filed 2022-03-01
2020-06-30-$2.48M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05
$5.68M
10-Q · filed 2021-08-05
$6.26M
derived: sum of 3 quarters · filed 2022-03-01
$17.63M
derived: sum of 4 quarters · filed 2022-03-01
2020-03-31$8.16M
10-Q · filed 2021-05-10
$8.74M
derived: sum of 2 quarters · filed 2022-03-01
$20.12M
derived: sum of 3 quarters · filed 2022-03-01
$21.24M
derived: sum of 4 quarters · filed 2022-03-01
2019-12-31$577.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01
$11.95M
derived: sum of 2 quarters · filed 2022-03-01
$13.08M
derived: sum of 3 quarters · filed 2022-03-01
$29.14M
10-K · filed 2022-03-01
2019-09-30$11.38M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$12.50M
derived: sum of 2 quarters · filed 2020-11-05
$28.57M
10-Q · filed 2020-11-05
2019-06-30$1.12M
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10
$17.19M
10-Q · filed 2020-08-10
2019-03-31$16.06M
10-Q · filed 2020-05-05
2018-12-31-$26.00K
10-K · filed 2021-02-25

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lyell Immunopharma, Inc. (LYEL)United States$0.248B-1.32
Pyxis Oncology, Inc. (PYXS)United States$0.244B
Greenwich LifeSciences, Inc. (GLSI)United States$0.267B-15.02
Entrada Therapeutics, Inc. (TRDA)United States$0.243B-1.73
Cue Biopharma, Inc. (CUE)United States$0.243B-1.01
MACROGENICS INC (MGNX)United States$0.242B-20.11
Mereo BioPharma Group plc (MREO)$0.269B-9.41
Camp4 Therapeutics Corp (CAMP)United States$0.240B-2.12
Sionna Therapeutics, Inc. (SION)United States$0.236B-20.37
SIGA TECHNOLOGIES INC (SIGA)United States$0.234B-93.33